Exact Sciences (NASDAQ:EXAS) Earns “Outperform” Rating from William Blair

William Blair reiterated their outperform rating on shares of Exact Sciences (NASDAQ:EXAS) in a research report released on Thursday,RTT News reports.

A number of other research firms have also recently commented on EXAS. Jefferies Financial Group boosted their price target on Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Evercore ISI lowered their price target on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. BTIG Research upped their price objective on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Citigroup decreased their price objective on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, Stifel Nicolaus decreased their price objective on Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $72.06.

Exact Sciences Stock Down 0.5 %

NASDAQ EXAS opened at $49.26 on Thursday. The stock’s 50 day moving average is $54.91 and its 200 day moving average is $60.01. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. Exact Sciences has a 12 month low of $40.62 and a 12 month high of $79.62. The stock has a market cap of $9.15 billion, a PE ratio of -8.84 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The company had revenue of $713.42 million for the quarter, compared to analysts’ expectations of $701.45 million. Research analysts predict that Exact Sciences will post -0.58 EPS for the current fiscal year.

Institutional Trading of Exact Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Thompson Investment Management Inc. grew its position in Exact Sciences by 17.8% in the 4th quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company’s stock valued at $13,585,000 after acquiring an additional 36,505 shares during the last quarter. WCM Investment Management LLC grew its position in Exact Sciences by 1,153.2% in the 3rd quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company’s stock valued at $12,388,000 after acquiring an additional 172,821 shares during the last quarter. Simplify Asset Management Inc. grew its position in Exact Sciences by 67.5% in the 3rd quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock valued at $1,994,000 after acquiring an additional 11,800 shares during the last quarter. Zacks Investment Management bought a new position in Exact Sciences in the 3rd quarter valued at $2,083,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Exact Sciences by 59.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock valued at $22,868,000 after acquiring an additional 125,192 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.